Skip to Main Content

Intellia Therapeutics said Monday that its CRISPR-based therapy for a genetic nerve disorder reduced the levels of a disease-causing protein by 93% in a new group of patients treated at the highest dose used to date — surpassing initial, lower-dose results reported last June.

The one-time Intellia therapy, called NTLA-2001, is also showing a sustained effect, with protein reductions remaining stable in previously treated patients followed for nine months, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment